Blinklab Limited
AASX:BB10.62
AUD
+0.00
(-0.81%)
ISIN
AU0000322851
Return %
Stock
S&P 500
1Y
-12.14
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Hendrikus Johannes Boele
- Full Time Employees
- 34
- Sector
- Technology services
- Industry
- Packaged software
- Address
- 216 St Georges Tce Sydney WA Australia 6000
- IPO Date
- Apr 2, 2024
- Website
- blinklab.org
- Similar Companies
- Business
- BlinkLab Ltd is a digital health company focused on smartphone-based neurobehavioral diagnostics and AI-powered analytics. It licenses its intellectual property to commercialize a smartphone application and secure online platform that perform neurometric tests to aid in diagnosing autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), schizophrenia, and related neurodevelopmental conditions; the system records test results on a smartphone and uploads data to BlinkLab’s confidential platform for analysis and reporting. BlinkLab operates primarily in Australia with research and development activities centered in Sydney, and it maintains partnerships and licensing arrangements that support the deployment of its diagnostic tools in clinical and research settings. The company emphasizes longitudinal data capture, remote testing capabilities, and integration with clinical workflows to support early detection and intervention strategies. BlinkLab was founded in 2021 and is headquartered in Sydney, Australia, with commercial activities and potential partnerships extending to global markets through licensing and collaborations. Subsidiaries and parent relationships are structured to enable IP licensing, platform hosting, and data security for healthcare applications. The core offering comprises the BlinkLab Dx product family, including diagnostic adjuncts and neurodevelopmental screening workflows, underpinned by AI and machine learning to enhance accuracy and accessibility. BlinkLab targets pediatric and clinical customers, including healthcare providers, researchers, and partner institutions seeking scalable, smartphone-enabled neurometric evaluations that complement traditional diagnostic pathways. The latest strategic updates reflect expanded licensing partnerships, ongoing product refinements, and prospective clinical collaborations to broaden adoption and support regulatory-compliant deployment in diverse jurisdictions.